Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding
Uterine leiomyomas are noncancerous smooth muscle neoplasms that occur in up to 70% of women and the single most common cause of hysterectomy. There is a variety of treatments available for uterine leiomyomas, including medications, uterine artery embolization, myomectomy, and hysterectomy but surgi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mary Ann Liebert
2025-01-01
|
| Series: | Women's Health Reports |
| Subjects: | |
| Online Access: | https://www.liebertpub.com/doi/10.1089/whr.2025.0013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275161764265984 |
|---|---|
| author | Danielle A. Aase Elizabeth A. Stewart |
| author_facet | Danielle A. Aase Elizabeth A. Stewart |
| author_sort | Danielle A. Aase |
| collection | DOAJ |
| description | Uterine leiomyomas are noncancerous smooth muscle neoplasms that occur in up to 70% of women and the single most common cause of hysterectomy. There is a variety of treatments available for uterine leiomyomas, including medications, uterine artery embolization, myomectomy, and hysterectomy but surgical treatments predominate. Medical optimization of anemia is often required prior to surgical treatment secondary to heavy menstrual bleeding and resultant iron deficiency anemia from chronic blood loss. While iron and multivitamins are critical to increase hemoglobin, pharmacologic therapy to suppress menstrual bleeding is often needed. First line therapy is typically a trial of combined oral contraceptive pills (OCPs); however, this may not be effective in all patients. Parenteral administration of long-acting GnRH agonists is often used as a second line treatment; however, these agents can lead to an initial “flare” effect precipitating a heavy bleed during the agonist phase which can be problematic in such patients. An alternative course of action is the use of oral GnRH antagonist combination therapy (OGAC) with estradiol and norethindrone, an option approved in both the United States and the European Union for long-term treatment of leiomyoma-related heavy menstrual bleeding. To demonstrate the clinical utility of OGAC therapy in the preoperative setting, we report a successful patient outcome and review relevant literature. |
| format | Article |
| id | doaj-art-5d7a620131fc4f77ac32cb1be2252065 |
| institution | OA Journals |
| issn | 2688-4844 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Mary Ann Liebert |
| record_format | Article |
| series | Women's Health Reports |
| spelling | doaj-art-5d7a620131fc4f77ac32cb1be22520652025-08-20T01:50:53ZengMary Ann LiebertWomen's Health Reports2688-48442025-01-016134134310.1089/whr.2025.0013Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual BleedingDanielle A. Aase0Elizabeth A. Stewart1Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic and Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic and Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.Uterine leiomyomas are noncancerous smooth muscle neoplasms that occur in up to 70% of women and the single most common cause of hysterectomy. There is a variety of treatments available for uterine leiomyomas, including medications, uterine artery embolization, myomectomy, and hysterectomy but surgical treatments predominate. Medical optimization of anemia is often required prior to surgical treatment secondary to heavy menstrual bleeding and resultant iron deficiency anemia from chronic blood loss. While iron and multivitamins are critical to increase hemoglobin, pharmacologic therapy to suppress menstrual bleeding is often needed. First line therapy is typically a trial of combined oral contraceptive pills (OCPs); however, this may not be effective in all patients. Parenteral administration of long-acting GnRH agonists is often used as a second line treatment; however, these agents can lead to an initial “flare” effect precipitating a heavy bleed during the agonist phase which can be problematic in such patients. An alternative course of action is the use of oral GnRH antagonist combination therapy (OGAC) with estradiol and norethindrone, an option approved in both the United States and the European Union for long-term treatment of leiomyoma-related heavy menstrual bleeding. To demonstrate the clinical utility of OGAC therapy in the preoperative setting, we report a successful patient outcome and review relevant literature.https://www.liebertpub.com/doi/10.1089/whr.2025.0013gynecologyGnRH antagonistleiomyomamyomectomy |
| spellingShingle | Danielle A. Aase Elizabeth A. Stewart Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding Women's Health Reports gynecology GnRH antagonist leiomyoma myomectomy |
| title | Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding |
| title_full | Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding |
| title_fullStr | Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding |
| title_full_unstemmed | Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding |
| title_short | Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding |
| title_sort | use of oral gonadotropin releasing hormone antagonist combinations for preoperative management of refractory leiomyoma related heavy menstrual bleeding |
| topic | gynecology GnRH antagonist leiomyoma myomectomy |
| url | https://www.liebertpub.com/doi/10.1089/whr.2025.0013 |
| work_keys_str_mv | AT danielleaaase useoforalgonadotropinreleasinghormoneantagonistcombinationsforpreoperativemanagementofrefractoryleiomyomarelatedheavymenstrualbleeding AT elizabethastewart useoforalgonadotropinreleasinghormoneantagonistcombinationsforpreoperativemanagementofrefractoryleiomyomarelatedheavymenstrualbleeding |